-
Tytuł:
-
Quantification of Etoposide Hypersensitivity: A Sensitive, Functional Method for Assessing Pluripotent Stem Cell Quality.
-
Autorzy:
-
Secreto FJ; Program for Hypoplastic Left Heart Syndrome-Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA.; Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Li X; Program for Hypoplastic Left Heart Syndrome-Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA.; Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA.
Smith AJ; Program for Hypoplastic Left Heart Syndrome-Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA.; Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Bruinsma ES; Program for Hypoplastic Left Heart Syndrome-Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA.; Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Perales-Clemente E; Program for Hypoplastic Left Heart Syndrome-Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Oommen S; Program for Hypoplastic Left Heart Syndrome-Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA.; Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Hawse G; Program for Hypoplastic Left Heart Syndrome-Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA.; Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Hrstka SCL; Program for Hypoplastic Left Heart Syndrome-Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA.; Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Arendt BK; Program for Hypoplastic Left Heart Syndrome-Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Brandt EB; Program for Hypoplastic Left Heart Syndrome-Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Wigle DA; Division of Thoracic Surgery, Mayo Clinic, Rochester, Minnesota, USA.; Center for Regenerative Medicine BioTrust, Mayo Clinic, Rochester, Minnesota, USA.
Nelson TJ; Program for Hypoplastic Left Heart Syndrome-Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA.; Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.; Transplant Center, Mayo Clinic, Rochester, Minnesota, USA.; Division of Pediatric Cardiology, Mayo Clinic, Rochester, Minnesota, USA.; Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.; Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
-
Źródło:
-
Stem cells translational medicine [Stem Cells Transl Med] 2017 Oct; Vol. 6 (10), pp. 1829-1839. Date of Electronic Publication: 2017 Sep 19.
-
Typ publikacji:
-
Journal Article; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Publication: 2022- : Oxford : Oxford University Press
Original Publication: Durham, NC : AlphaMed Press
-
MeSH Terms:
-
Colony-Forming Units Assay/*methods
Etoposide/*pharmacology
Induced Pluripotent Stem Cells/*drug effects
Topoisomerase Inhibitors/*pharmacology
Cells, Cultured ; Clinical Trials as Topic ; Humans ; Induced Pluripotent Stem Cells/metabolism ; Transcriptome
-
References:
-
Lab Invest. 1993 Feb;68(2):220-32. (PMID: 7680083)
Curr Biol. 1998 Jan 29;8(3):145-55. (PMID: 9443911)
J Natl Cancer Inst. 1974 Nov;53(5):1341-9. (PMID: 4431054)
PLoS One. 2015 Feb 23;10(2):e0118670. (PMID: 25706534)
Nat Methods. 2014 Aug;11(8):855-60. (PMID: 24930130)
Biochem J. 2011 Feb 15;434(1):25-35. (PMID: 21269276)
Curr Protoc Hum Genet. 2015 Oct 06;87:21.3.1-21.3.15. (PMID: 26439715)
Cancer Res. 1984 Dec;44(12 Pt 1):5857-60. (PMID: 6094001)
Cell Stem Cell. 2008 Dec 4;3(6):595-605. (PMID: 19041776)
Differentiation. 1988;37(1):73-9. (PMID: 2898410)
Wiley Interdiscip Rev Dev Biol. 2016 Mar-Apr;5(2):186-209. (PMID: 26698368)
Cell Cycle. 2011 Jun 15;10(12):2035-7. (PMID: 21673500)
Stem Cell Reports. 2017 Apr 11;8(4):1101-1111. (PMID: 28410643)
Shi Yan Sheng Wu Xue Bao. 1995 Dec;28(4):397-407. (PMID: 8731971)
Stem Cells Transl Med. 2015 Jun;4(6):576-89. (PMID: 25900727)
J Natl Cancer Inst. 1974 Mar;52(3):921-30. (PMID: 4524119)
PLoS One. 2010 Oct 15;5(10):e13410. (PMID: 20976220)
Nat Methods. 2011 Apr;8(4):315-7. (PMID: 21378979)
Methods Mol Biol. 2015;1283:13-21. (PMID: 25537838)
Glycobiology. 2014 May;24(5):458-68. (PMID: 24578376)
Differentiation. 1990 Apr;43(2):123-30. (PMID: 2373285)
Nat Rev Drug Discov. 2015 Oct;14(10):681-92. (PMID: 26391880)
Stem Cell Rev Rep. 2014 Apr;10(2):177-90. (PMID: 24425421)
Carcinogenesis. 1999 Oct;20(10):1899-903. (PMID: 10506102)
Cancer Res. 1980 Mar;40(3):796-802. (PMID: 7471097)
Nat Med. 2011 Mar;17(3):313-9. (PMID: 21386835)
Sci Rep. 2016 Sep 26;6:34009. (PMID: 27667091)
Stem Cells. 2013 Jul;31(7):1298-308. (PMID: 23553816)
Stem Cells. 2014 Sep;32(9):2350-9. (PMID: 24802033)
Biochem Biophys Res Commun. 1984 Jul 18;122(1):165-70. (PMID: 6331440)
Int J Androl. 1987 Feb;10(1):105-13. (PMID: 3034787)
Radiat Res. 2016 Jul;186(1):17-26. (PMID: 27332952)
Cell. 2011 Feb 4;144(3):439-52. (PMID: 21295703)
Eur J Cancer. 1998 Sep;34(10):1514-21. (PMID: 9893622)
Nat Biotechnol. 2015 Nov;33(11):1182-92. (PMID: 26501952)
Stem Cell Reports. 2015 Jun 9;4(6):967-74. (PMID: 26070610)
EMBO J. 2016 Sep 15;35(18):1979-90. (PMID: 27436875)
Dev Biol. 1984 Jun;103(2):285-93. (PMID: 6144603)
Stem Cells Transl Med. 2014 Apr;3(4):500-9. (PMID: 24493856)
Hybridoma. 1984 Winter;3(4):347-61. (PMID: 6396197)
J Biol Chem. 1984 Nov 10;259(21):13560-6. (PMID: 6092381)
Stem Cell Res. 2007 Nov;1(2):116-28. (PMID: 19383392)
Lab Invest. 1984 Feb;50(2):147-62. (PMID: 6694356)
Int J Cancer. 1982 May 15;29(5):523-31. (PMID: 7095898)
Nature. 2016 Jun 15;534(7607):310-2. (PMID: 27306170)
Stem Cells Transl Med. 2012 Oct;1(10):709-18. (PMID: 23197662)
-
Contributed Indexing:
-
Keywords: Etoposide; Functional; Hypersensitivity; Pluripotent stem cells; Quantification
-
Substance Nomenclature:
-
0 (Topoisomerase Inhibitors)
6PLQ3CP4P3 (Etoposide)
-
Entry Date(s):
-
Date Created: 20170920 Date Completed: 20190628 Latest Revision: 20200306
-
Update Code:
-
20240104
-
PubMed Central ID:
-
PMC6430057
-
DOI:
-
10.1002/sctm.17-0116
-
PMID:
-
28924979
-
Human induced pluripotent stem cells (hiPSC) hold great promise in diagnostic and therapeutic applications. However, translation of hiPSC technology depends upon a means of assessing hiPSC quality that is quantitative, high-throughput, and can decipher malignant teratocarcinoma clones from normal cell lines. These attributes are lacking in current approaches such as detection of cell surface makers, RNA profiling, and/or teratoma formation assays. The latter remains the gold standard for assessing clone quality in hiPSCs, but is expensive, time-consuming, and incompatible with high-throughput platforms. Herein, we describe a novel method for determining hiPSC quality that exploits pluripotent cells' documented hypersensitivity to the topoisomerase inhibitor etoposide (CAS No. 33419-42-0). Based on a study of 115 unique hiPSC clones, we established that a half maximal effective concentration (EC50) value of <300 nM following 24 hours of exposure to etoposide demonstrated a positive correlation with RNA profiles and colony morphology metrics associated with high quality hiPSC clones. Moreover, our etoposide sensitivity assay (ESA) detected differences associated with culture maintenance, and successfully distinguished malignant from normal pluripotent clones independent of cellular morphology. Overall, the ESA provides a simple, straightforward method to establish hiPSC quality in a quantitative and functional assay capable of being incorporated into a generalized method for establishing a quality control standard for all types of pluripotent stem cells. Stem Cells Translational Medicine 2017;6:1829-1839.
(© 2017 The Authors Stem Cells Translational Medicine published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.)
